Horse Anti-Rabies Virus IgG (Fab2), neutralizing |
|
RBV16-Fab2 |
Alpha Diagnostics |
100 ul |
EUR 534 |
Human IgG antibody Laboratories manufactures the vaccinia virus neutralizing antibody assay reagents distributed by Genprice. The Vaccinia Virus Neutralizing Antibody Assay reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact virus assay. Other Vaccinia products are available in stock. Specificity: Vaccinia Category: Virus Group: Neutralizing Antibody
Rsv-neutralizing Human Antibody |
|
MyBiosource |
1mg |
EUR 1380 |
Rsv-neutralizing Human Antibody |
|
MyBiosource |
5x1mg |
EUR 5825 |
Rsv-neutralizing Human Antibody |
|
MyBiosource |
0.1mg |
EUR 410 |
Rsv-neutralizing Human Antibody |
|
MyBiosource |
1mg |
EUR 1380 |
Rsv-neutralizing Human Antibody |
|
MyBiosource |
5x1mg |
EUR 5825 |
SeroFlash SARS-CoV-2 Neutralizing Antibody Assay Fast Kit |
|
EpiGentek |
48 Assays |
EUR 539 |
Human Anti-Varicella Zoster Virus Antibody IgG Titer Serologic Assay Kit (gE) |
|
ACROBIOSYSTEMS |
96tests |
EUR 631.3 |
|
|
|
Description: Varicella-zoster virus (VZV) the etiologic agent of chickenpox and herpes zoster [HZ], is highly contagious and still endemic worldwide. Glycoprotein E (gE) is one of the known glycoproteins (gB, gC, gE, gH, gI, gK, gI) of VZV that is most abundantly expressed on the surface of virus and infected cells, playing an important role in viral replication and cell-to-cell spread. The strongly immunogenic gE can provide strong IgG signal in body fluid, which makes it ideal to be developed as an antigen for analysis of Immunogenicity in the development of VZV vaccine.Therefore,It's helpful to develop the Human Anti-Varicella Zoster Virus Antibody IgG Titer Serologic Assay Kit (gE) to detection the IgG(GE) titer level in mouse serum during the clinical stage of vaccine development. |
Neutralizing Antibody information
Anti-Human respiratory syncytial virus(RSV) Fusion glycoprotein/RSV-F Neutralizing Antibody |
|
E-AB-V1272-100uL |
Elabscience Biotech |
100uL |
EUR 200 |
|
|
|
Description: Unconjugated |
Anti-Human respiratory syncytial virus(RSV) Fusion glycoprotein/RSV-F Neutralizing Antibody |
|
E-AB-V1272-200uL |
Elabscience Biotech |
200uL |
EUR 300 |
|
|
|
Description: Unconjugated |
Anti-Human respiratory syncytial virus(RSV) Fusion glycoprotein/RSV-F Neutralizing Antibody |
|
E-AB-V1272-500uL |
Elabscience Biotech |
500uL |
EUR 465 |
|
|
|
Description: Unconjugated |
Anti-Human respiratory syncytial virus(RSV) Fusion glycoprotein/RSV-F Neutralizing Antibody |
|
E-AB-V1272-each |
Elabscience Biotech |
each |
Ask for price |
|
|
|
Description: Unconjugated |
Anti-Human respiratory syncytial virus (RSV) Fusion glycoprotein/RSV-F Neutralizing Antibody |
|
MBS2563973-01mL |
MyBiosource |
0.1mL |
EUR 235 |
Anti-Human respiratory syncytial virus (RSV) Fusion glycoprotein/RSV-F Neutralizing Antibody |
|
MBS2563973-02mL |
MyBiosource |
0.2mL |
EUR 310 |
Anti-Human respiratory syncytial virus (RSV) Fusion glycoprotein/RSV-F Neutralizing Antibody |
|
MBS2563973-05mL |
MyBiosource |
0.5mL |
EUR 455 |
Anti-Human respiratory syncytial virus (RSV) Fusion glycoprotein/RSV-F Neutralizing Antibody |
|
MBS2563973-5x05mL |
MyBiosource |
5x0.5mL |
EUR 2015 |
Human respiratory syncytial virus (RSV) Fusion glycoprotein/RSV-F Neutralizing Antibody(HRP) |
|
MBS8124087-01mg |
MyBiosource |
0.1mg |
EUR 375 |
Human respiratory syncytial virus (RSV) Fusion glycoprotein/RSV-F Neutralizing Antibody(HRP) |
|
MBS8124087-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1545 |
Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody |
|
abx411283-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
|
Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody |
|
abx411283-100g |
Abbexa |
100 µg |
Ask for price |
Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody |
|
abx411283-25g |
Abbexa |
25 µg |
EUR 487.5 |
SARS-CoV-2 Omicron Subvariants Neutralizing Antibody 5-plex Panel (Flow Cytometry Multiplex Bead Assay) |
|
FCM-N06R |
ACROBIOSYSTEMS |
96tests |
EUR 1187.7 |
|
|
|
Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide. Omicron is a variant of SARS-CoV-2 first detected in November 2021 and is causing the ongoing COVID-19 pandemic. The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. Its recent descendants BA.2.12.1 and BA.4/5 have surged dramatically to become dominant in the United States and South Africa, respectively. BA.2.12.1 and BA.4/BA.5 exhibit comparable ACE2-binding affinities to BA.2. Importantly, BA.2.12.1 and BA.4/BA.5 display stronger neutralization evasion than BA.2 against the plasma from 3-dose vaccination and, most strikingly, from post-vaccination BA.1 infections. |
IL-6 Neutralizing Antibody |
|
MBS8102624-02mg |
MyBiosource |
0.2mg |
EUR 280 |
IL-6 Neutralizing Antibody |
|
MBS8102624-05mg |
MyBiosource |
0.5mg |
EUR 375 |
IL-6 Neutralizing Antibody |
|
MBS8102624-5x05mg |
MyBiosource |
5x0.5mg |
EUR 1545 |
